Use of Meriva as complementary therapy of locally advanced or metastatic pancreatic cancer (PC) with gemcitabine (GEM).

被引：1
|
作者：
Solda, Caterina
Sperti, Cosimo
Romeo, Bardini
Da Dalt, Gianfranco
Gion, Massimo
Ursini, Fulvio
Fiduccia, Pasquale
Aliberti, Camillo
Pastorelli, Davide
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15696
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15696
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer
    Hammad, N.
    Philip, P. A.
    Shields, A. F.
    Sarkar, F. H.
    Abruzzese, J. L.
    Kaseb, A. O.
    Javle, M. M.
    Varadhachary, G. R.
    Wolff, R. A.
    El-Rayes, B. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] FOLFIRINOX in locally advanced or metastatic pancreatic cancer
    Faris, Jason Edward
    Hong, Theodore S.
    McDermott, Shaunagh
    Guimaraes, Alexander R.
    Sahani, Dushyant
    Clark, Jeffrey W.
    Ryan, David P.
    Blaszkowsky, Lawrence Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [33] Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
    Shinoto, Makoto
    Yamada, Shigeru
    Terashima, Kotaro
    Yasuda, Shigeo
    Shioyama, Yoshiyuki
    Honda, Hiroshi
    Kamada, Tadashi
    Tsujii, Hirohiko
    Saisho, Hiromitsu
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 95 (01): : 498 - 504
  • [34] PEFG salvage therapy inpatients with gemcitabine-resistant advanced pancreatic cancer (PC)
    Cereda, S.
    Mazza, E.
    Passoni, P.
    Nicoletti, R.
    Balzano, G.
    Zerbi, A.
    Staudacher, C.
    di Carlo, V
    Reni, M.
    ANNALS OF ONCOLOGY, 2006, 17 : 58 - 59
  • [35] PEFG salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer (PC)
    Cereda, S.
    Mazza, E.
    Vitali, G.
    Passoni, P.
    Balzano, G.
    Zerbi, A.
    Staudacher, C.
    Di Carlo, V
    Reni, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI50 - XI50
  • [36] Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer
    Heinemann, V
    Wilke, H
    Mergenthaler, HG
    Clemens, M
    König, H
    Illiger, HJ
    Arning, M
    Schalhorn, A
    Possinger, K
    Fink, U
    ANNALS OF ONCOLOGY, 2000, 11 (11) : 1399 - 1403
  • [37] ASSOCIATION OF GEMCITABINE (GEM) AND OXALIPLATIN (OXA) IN METASTATIC OR LOCALLY ADVANCED PANCREATIC ADENO-CARCINOMA: A CLINICAL AND PHARMACOKINETIC (PK) STUDY
    Airoldi, M.
    Cattel, L.
    Passera, R.
    Micari, C.
    Nigro, A.
    Milla, P.
    ANNALS OF ONCOLOGY, 2004, 15 : 68 - 68
  • [38] Improvements in survival and clinical benefit with the use of gemcitabine (GEM) as first-line therapy for advanced pancreatic cancer: A randomized trial
    Moore, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 547 - 547
  • [39] Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
    Fogelman, David
    Jafari, Mehrdad
    Varadhachary, Gauri R.
    Xiong, Henry
    Bullock, Susie
    Ozer, Harold
    Lin, E.
    Morris, Jeffrey
    Cunningham, Patti
    Bennett, Bronwyn
    Abbruzzese, James L.
    Wolff, Robert A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1431 - 1438
  • [40] Pilot Study of Hypofractionated Radiation Therapy for Locally Advanced and Metastatic Pancreatic Cancer
    Wang, J.
    Xia, T.
    Qu, B. L.
    Zhang, H. J.
    Ma, L.
    Feng, L. C.
    Cai, B. N.
    Xu, S. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E130 - E130
12345